ReviR Therapeutics and LTZ Therapeutics Secure Tens of Millions in USD Funding to Advance Pipeline Development

　　【Pharmaceutical Network Industry DynamicsOn July 30, several pharmaceutical companies, including ReviR Therapeutics and LTZ Therapeutics, announced that they had completed multi-million-dollar financing rounds, which will help accelerate the development of their product pipelines.
 

　　LTZ Therapeutics: Completed Over $20 Million Series A Financing
 

LTZ Therapeutics announced that the company has completed a Series A financing round of over 20 million US dollars. This round of financing was led by Lapam Capital, with participation from Hillhouse Ventures, and additional investments from existing shareholders such as Qiming Venture Partners, K2VC, and Shunwei Capital.
 

It is reported that the newly raised funds from this round will be mainly used to accelerate the development of the LTZ pipeline, including filing for Investigational New Drug (IND) applications, initiating Phase I clinical trials for the first product, LTZ-301, and conducting IND-enabling studies for the second product, LTZ-232, as well as rapidly advancing other ongoing projects. Additionally, the funds will be used to further expand the global team.
 

Public information shows that LTZ Therapeutics is a biotechnology company focused on immunotherapy, dedicated to developing new therapies to improve clinical outcomes for cancer and other diseases with unmet clinical needs.
 

Currently, the company is developing its own broad-spectrum natural immune cell multi-functional antibody platform, and plans to complete the preclinical validation of the natural immune multi-functional antibody platform and the IND-enabling work for the first drug candidate this year. The company aims to file an IND application early next year and initiate the first-in-human clinical study.
 

　　ReviR Therapeutics: Completes $30 Million Series A Financing
 

ReviR Therapeutics announced the completion of its $30 million Series A financing round, led by Lapam Capital, with continued investment from CDH Investments, 5Y Capital, and Yabai Capital, as well as participation from XtalPi and the CMT Research Foundation.
 

Public information shows that ReviR Therapeutics focuses on drug development for neurodegenerative diseases and other hereditary rare diseases. By leveraging its self-developed AI drug discovery platform VoyageR, which combines AI technology with the team's extensive experience in drug development, the company has continued to achieve breakthroughs across multiple disease areas.
 

Currently, through self-research and collaboration, ReviR Therapeutics has established pipelines covering multiple neurological diseases such as Charcot-Marie-Tooth disease, ALS, and cerebellar ataxia. Among them, the self-developed pipeline for Huntington's disease is progressing relatively faster.
 

Huntington's disease is an autosomal dominant hereditary neurodegenerative disorder caused by the CAG-CAA repeat expansion in the Huntington (HTT) gene that encodes polyglutamine, characterized mainly by chronic progressive choreiform movements, cognitive dysfunction, and psychiatric behavioral abnormalities. Current therapies can only alleviate symptoms and cannot slow disease progression.
 

It is reported that the drug under research by ReviR Therapeutics can reduce mutant huntingtin protein, delaying or blocking the disease progression at the genetic level. The drug is expected to enter Phase I clinical trials in 2025.
 

Moreover, ReviR Therapeutics' pipeline for Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease) is currently making considerable progress. ALS is a rare disease that affects the upper and lower motor neurons and the muscles of the trunk, limbs, and bulbar region they control, characterized as a chronic and progressive degenerative disorder. The ALS drug under development by ReviR Therapeutics is expected to file an IND and commence Phase I clinical trials by early 2025.
 

It is reported that the proceeds of this round of financing will be mainly used for further construction of the VoyageR platform and continued advancement of preclinical and clinical stage development of multiple pipelines related to neurological diseases such as Huntington's disease (HD), Charcot-Marie-Tooth disease (CMT), and amyotrophic lateral sclerosis (ALS).
 

Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to any person.